Pain News and Research

Latest Pain News and Research

First Edition: September 12, 2012

Today's headlines include news about former President Bill Clinton's role on the presidential campaign trail as well as reports from Capitol Hill and details of a new survey regarding health insurance costs.

12 Sep 2012

Annual economic cost of chronic pain is as high as $635 billion: Study

Health economists from Johns Hopkins University writing in The Journal of Pain (www.jpain.org) reported the annual cost of chronic pain is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.

12 Sep 2012

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Sucampo Pharmaceuticals, Inc. today announced that it has received approval from the Medicines and Healthcare products Regulatory Agency for AMITIZA (lubiprostone) 24 mcg twice daily for the treatment of chronic idiopathic constipation (CIC) and associated symptoms in adults, when response to diet and other non-pharmacological measures (e.g., educational measures, physical activity) are inappropriate.

12 Sep 2012

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

"The leading candidate to become the world's first vaccine against dengue fever was only 30 percent effective in its first large clinical trial, dealing at least a temporary setback to efforts to control a disease that threatens half the world's population," the New York Times reports.

12 Sep 2012

Study evaluates distribution and severity of pain in sexual assault victims

A majority of sexual assault victims experience severe pain in the early aftermath of the crime but less than a third of these victims receive pain medications, according to research in The Journal of Pain, the peer review publication of the American Pain Society.

12 Sep 2012

HSS receives NFL grant for research into platelet-rich plasma and stem cells

Researchers at Hospital for Special Surgery have been awarded a $100,000 grant from the National Football League (NFL) Charities to research the use of platelet-rich plasma (PRP) and stem cells as treatments for tendon injury and degeneration. For years, PRP has been used to improve healing in various sports injuries, but there is little evidence of its efficacy.

12 Sep 2012

Inhaled analgesia appears to be effective in reducing pain intensity in first stage of labour

Inhaled pain relief appears to be effective in reducing pain intensity and in giving pain relief in the first stage of labour, say Cochrane researchers.

12 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

Instrument-assisted spinal manipulation shows hypoalgesic effects

Instrument-assisted spinal manipulative therapy targeted to the low-back region has an immediate and widespread hypoalgesic effect, say researchers.

11 Sep 2012

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Although people often say they have "strep" throat, most sore throats actually are caused by a virus, not streptococcus bacteria, and shouldn't be treated with antibiotics, suggest guidelines published by the Infectious Diseases Society of America (IDSA). Antibiotics are ineffective against viruses.

11 Sep 2012

Pediatric pain: An interview with Lori Kozlowski

The pain experienced by the infants, children and adolescents in our study was the result of a broad range of medical and surgical conditions.

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).

11 Sep 2012

More patients gain weight after joint replacement surgery

Hip and knee replacements are now a common surgical procedure with more than 700,000 total joint arthroplasties (TJAs) performed in the US every year. Due to the reduction in pain and increases in mobility experienced after having a TJA, it could be expected that weight loss may occur as a by-product of the surgery.

10 Sep 2012

Annovation Biopharma to develop novel anesthetics with $8M Series A financing

Annovation Biopharma, a biotechnology company focused on creating more effective, safer therapies for anesthesia and critical care, has raised $8M in a Series A financing led by Atlas Venture, Partners Innovation Fund, and new strategic investor The Medicines Company.

10 Sep 2012

Physician empathy has positive impact on patient outcomes

Patients of doctors who are more empathic have better outcomes and fewer complications, concludes a large, empirical study by a team of Thomas Jefferson University and Italian researchers who evaluated relationships between physician empathy and clinical outcomes among 20,961 diabetic patients and 242 physicians in Italy.

10 Sep 2012

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

BioLineRx, a biopharmaceutical development company, announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date.

10 Sep 2012

Baylor Health Care System raises awareness about atrial fibrillation

An estimated 2.5 million Americans suffer from irregular heartbeats-also known as atrial fibrillation. Baylor Health Care System is raising awareness about this often misunderstood, but potentially life changing cardiovascular condition whose incidence is on the rise and expected to more than double by 2050.

10 Sep 2012

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.

7 Sep 2012